358 related articles for article (PubMed ID: 33721334)
1. Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
Wilkins LJ; Tosoian JJ; Reichard CA; Sundi D; Ranasinghe W; Alam R; Schwen Z; Reddy C; Allaf M; Davis JW; Chapin BF; Ross AE; Klein EA; Nyame YA
Cancer; 2021 May; 127(9):1425-1431. PubMed ID: 33721334
[TBL] [Abstract][Full Text] [Related]
2. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
3. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.
Moses KA; Chen LY; Sjoberg DD; Bernstein M; Touijer KA
BMC Urol; 2014 Dec; 14():98. PubMed ID: 25495177
[TBL] [Abstract][Full Text] [Related]
4. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men.
Eastham JA; Carver B; Katz J; Kattan MW
Prostate; 2002 Mar; 50(4):236-40. PubMed ID: 11870801
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy.
Bianco FJ; Wood DP; Grignon DJ; Sakr WA; Pontes JE; Powell IJ
J Urol; 2002 Aug; 168(2):479-82. PubMed ID: 12131292
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
7. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up.
Faisal FA; Sundi D; Cooper JL; Humphreys EB; Partin AW; Han M; Ross AE; Schaeffer EM
Urology; 2014 Dec; 84(6):1434-41. PubMed ID: 25432835
[TBL] [Abstract][Full Text] [Related]
8. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
9. Comparing the outcomes of robotic assisted radical prostatectomy in black and white men: Experience of a high-volume center.
Noël J; Moschovas MC; Sandri M; Jaber AR; Rogers T; Patel V
Int Braz J Urol; 2022; 49(1):123-135. PubMed ID: 36512460
[TBL] [Abstract][Full Text] [Related]
10. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
Lediju O; Ikuemonisan J; Salami SS; Adejoro O
J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
[TBL] [Abstract][Full Text] [Related]
11. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
[TBL] [Abstract][Full Text] [Related]
12. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
Schulman AA; Howard LE; Tay KJ; Tsivian E; Sze C; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ; Polascik TJ
Cancer; 2017 Nov; 123(21):4122-4129. PubMed ID: 28662291
[TBL] [Abstract][Full Text] [Related]
13. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer.
Eastham JA; Kattan MW
J Urol; 2000 Jan; 163(1):143-5. PubMed ID: 10604332
[TBL] [Abstract][Full Text] [Related]
14. [Impact of Gleason score on biochemical recurrence free survival after radical prostatectomy with positive surgical margins].
Roux V; Eyraud R; Brureau L; Gourtaud G; Senechal C; Fofana M; Blanchet P
Prog Urol; 2017; 27(8-9):467-473. PubMed ID: 28576421
[TBL] [Abstract][Full Text] [Related]
15. Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study.
Amini E; Palmer TC; Cai J; Lieskovsky G; Daneshmand S; Djaladat H
World J Urol; 2018 Aug; 36(8):1233-1239. PubMed ID: 29536157
[TBL] [Abstract][Full Text] [Related]
16. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
[TBL] [Abstract][Full Text] [Related]
17. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
Cancer; 2007 Nov; 110(10):2202-9. PubMed ID: 17876838
[TBL] [Abstract][Full Text] [Related]
18. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.
Sundi D; Kryvenko ON; Carter HB; Ross AE; Epstein JI; Schaeffer EM
J Urol; 2014 Jan; 191(1):60-7. PubMed ID: 23770146
[TBL] [Abstract][Full Text] [Related]
19. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity.
Underwood W; Wei J; Rubin MA; Montie JE; Resh J; Sanda MG
Urol Oncol; 2004; 22(1):20-4. PubMed ID: 14969799
[TBL] [Abstract][Full Text] [Related]
20. Overall, specific, and metastasis-free survival of Afro-Caribbean men with pathological Gleason 6 prostate cancer.
Mollard P; Perrot E; Blanchet P; Brureau L
Prostate; 2020 Mar; 80(4):329-335. PubMed ID: 31868959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
